INHIBITION OF FLT3 SIGNALING BOTH IN VITRO AND IN VIVO BY AC220, A SECOND GENERATION POTENT AND SELECTIVE FLT3 INHIBITOR

被引：0
|
作者：
Armstrong, R. [1 ]
Gunawardane, R. [1 ]
Rooks, A. [1 ]
Dao, A. [1 ]
Ricono, J. [1 ]
Brigham, D. [1 ]
Zarrinkar, P. [1 ]
Belli, B. [1 ]
Wierenga, W. [1 ]
机构：
[1] Ambit Biosci, San Diego, CA USA
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：34 / 34
页数：1
相关论文
共 50 条
  • [1] AC220 Is a Uniquely Potent and Selective Second-Generation FLT3 Inhibitor
    Zarrinkar, Patrick P.
    Armstrong, Robert C.
    Gunawardane, Ruwanthi N.
    James, Joyce
    Karaman, Mazen W.
    Bhagwat, Shripad S.
    BLOOD, 2008, 112 (11) : 318 - 318
  • [2] Clinical Pharmacokinetics and FLT3 Phosphorylation of AC220, a Highly Potent and Selective Inhibitor of FLT3
    James, Joyce
    Pratz, Keith
    Stine, Adam
    Apuy, Julius L.
    Insko, Darren E.
    Armstrong, Robert C.
    Zarrinkar, Patrick P.
    Small, Donald
    Wierenga, Wendell
    Levis, Mark J.
    BLOOD, 2008, 112 (11) : 912 - 912
  • [3] FLT3 inhibitor quizartinib (AC220)
    Naqvi, Kiran
    Ravandi, Farhad
    LEUKEMIA & LYMPHOMA, 2019, 60 (08) : 1866 - 1876
  • [4] Phase 1 AML Study of AC220, a Potent and Selective Second Generation FLT3 Receptor Tyrosine Kinase Inhibitor
    Cortes, Jorge E.
    Ghirdaladze, Darejan
    Foran, James M.
    DeVetten, Marcel P.
    Zodelava, Mamia
    Levis, Mark J.
    Padre, Norman M.
    Joyce, James
    Zarrinkar, Patrick P.
    Corringham, Robert
    BLOOD, 2008, 112 (11) : 284 - 285
  • [5] Characterization of the biochemical and cellular activity of the second-generation FLT3 inhibitor AC220
    Zarrinkar, Patrick
    Armstrong, Robert
    Gunawardane, Ruwanthi
    James, Joyce
    Karaman, Mazen
    Bhagwat, Shripad
    CANCER RESEARCH, 2009, 69
  • [6] AC220, a uniquely potent and selective FLT3 inhibitor, provides sustained protection in a FLT3 ITD driven model of acute myeloid leukemia
    Belli, Barbara
    Brigham, Daniel
    Breider, Michael
    Bhagwat, Shripad
    Armstrong, Robert
    CANCER RESEARCH, 2009, 69
  • [7] Terminal Differentiation of FLT3/ITD AML Blasts In Patients Treated with the FLT3 Inhibitor AC220
    Levis, Mark J.
    Sexauer, Amy
    Rajkhowa, Trivikram
    Small, Donald
    Borowitz, Michael J.
    BLOOD, 2010, 116 (21) : 288 - 289
  • [8] Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling
    Taylor, Samuel J.
    Dagger, Samantha A.
    Thien, Christine B. F.
    Wikstrom, Matthew E.
    Langdon, Wallace Y.
    BLOOD, 2012, 120 (19) : 4049 - 4057
  • [9] AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
    Zarrinkar, Patrick P.
    Gunawardane, Ruwanthi N.
    Cramer, Merryl D.
    Gardner, Michael F.
    Brigham, Daniel
    Belli, Barbara
    Karaman, Mazen W.
    Pratz, Keith W.
    Pallares, Gabriel
    Chao, Qi
    Sprankle, Kelly G.
    Patel, Hitesh K.
    Levis, Mark
    Armstrong, Robert C.
    James, Joyce
    Bhagwat, Shripad S.
    BLOOD, 2009, 114 (14) : 2984 - 2992
  • [10] DISRUPTING CDKN1A SECONDARY TO FLT3/ITD INHIBITION IS RESPONSIBLE FOR RESISTANCE TO FLT3/ITD INHIBITOR AC220 IN FLT3/ITD+ CELLS
    Fukuda, Seiji
    Abe, Mariko
    Hirade, Tomohiro
    Yamaguchi, Seiji
    EXPERIMENTAL HEMATOLOGY, 2015, 43 (09) : S63 - S63
12345